Clinical Trials

Retina Clinical Trials

This study is a phase 2 trial which evaluates the safety and efficacy of the IBE-814 IVT dexamethasone implant in patients with DMO. Sustained dexamethasone will be released to the retina over 6 months. Patients will receive a single high dose IBE-814 IVT implant. ie. 2x implants injected into the vitreous humour.

This is a phase 2 study evaluating the safety of EXN407 eye drops in those with centre-involved DMO, secondary to diabetes mellitus. This is a first in humans (FIH) study examining safety and tolerability of the eye drop. EXN407 is a selective SRPK1 inhibitor and designed to have great ocular permeability and reach the retina/choroid. In the first phase (escalation phase), participants will self-administer the eye drops twice a day for 7 days. Following this, the expansion phase will involve participants administering eye drops twice a day for 84 days.

This is a phase 3 double masked study investigating safety and efficacy of intravitreal faricimab in patients with macular oedema secondary to branch retinal vein occlusions (BRVO). Faricimab or sham will be given monthly until end of study at Week 72.

This is a phase 3 double masked study investigating safety and efficacy of intravitreal faricimab in patients with macular oedema secondary to central retinal vein occlusions (CRVO) or hemiretinal vein occlusions (HRVO). Faricimab or sham will be given monthly until end of study at Week 72.

The CUREOS Clinical Research Network provides research trials, site management and medical writing.